Skip to main content
Medesis Pharma S.A. logo

Medesis Pharma S.A. — Investor Relations & Filings

Ticker · ALMDP ISIN · FR0010844464 LEI · 969500C15M96P00UR648 PA Manufacturing
Open in API
Filings indexed 118 across all filing types
Latest filing 2022-04-21 Audit Report / Informat…
Country FR France
Listing PA ALMDP

About Medesis Pharma S.A.

https://www.medesispharma.com/

Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.

Recent filings

Filing Released Lang Actions
MEDESIS PHARMA - RAPPORT FINANCIER ANNUEL 2021
Audit Report / Information Classification · 98% confidence The document is explicitly titled "RAPPORT FINANCIER ANNUEL" (Annual Financial Report) and contains a detailed "Rapport de gestion sur les comptes sociaux" (Management report on the annual accounts) for the year ended December 31, 2021. It includes sections like Attestation of responsibility, financial results, R&D activity, management remuneration, and the report of the Statutory Auditors on the annual accounts. This structure and content are characteristic of a comprehensive annual report, which aligns with the definition of a 10-K, even though the document is in French and likely filed with a European regulator (given the mention of RCS Montpellier and ANSM). Since '10-K' is the standard code for the official yearly report covering full financial performance, it is the most appropriate classification among the provided options. FY 2021
2022-04-21 French
MEDESIS PHARMA - Mise à disposition du Rapport Financier Annuel 2021
Audit Report / Information Classification · 98% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and explicitly states that Medesis Pharma has made available ("Mise à disposition") and filed the "Rapport Financier Annuel 2021" (Annual Financial Report 2021) with the AMF. The text mentions that the report can be consulted and downloaded from the company website. Since the document itself is a short announcement (2808 characters) whose primary purpose is to inform the public that a major report (the Annual Financial Report) has been published and is available elsewhere, it fits the definition of a Report Publication Announcement (RPA). It is not the full 10-K report itself, but the announcement of its availability. FY 2021
2022-04-21 French
Medesis Pharma : Développement du NanoManganèse pour l’optimisation de la radiothérapie en traitement des cancers
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'COMMUNIQUÉ DE PRESSE' (Press Release) and announces positive preclinical results regarding the NanoManganese candidate for optimizing radiotherapy in cancer treatment. It details scientific findings, collaboration with IRBA, and future clinical plans, including financing needs. This format—a formal announcement of significant operational/scientific news rather than a mandated regulatory filing (like 10-K, IR, or DEF 14A) or a transcript—best fits the general 'Regulatory Filings' or 'Earnings Release' categories. Since it is a scientific/development update and not a financial results summary (ER), and it doesn't fit any other specific category (like M&A, Capital Change, or Dividend), it defaults to the general regulatory announcement category, RNS, as it is a formal communication to the market about a material development.
2022-04-20 French
MEDESIS PHARMA : Development of NanoManganese for the optimization of radiotherapy in cancer treatment
Regulatory Filings Classification · 92% confidence The document is a press release announcing positive preclinical results regarding the development of NanoManganese for optimizing radiotherapy in cancer treatment. It details scientific findings, study objectives, and future financing/clinical plans. This type of announcement, focusing on scientific progress and development pipeline updates, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a press release detailing scientific/development progress rather than a formal regulatory filing (like 10-K or IR) or a specific financial event (like ER or DIV), and it serves to inform investors about the company's progress, 'Investor Presentation' (IP) is the most fitting category, although it is presented as a press release. Given the options, 'IP' covers detailed strategic and scientific updates aimed at investors. It is not a formal Earnings Release (ER) or a comprehensive Interim Report (IR).
2022-04-20 English
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS ANNUELS 2021
Earnings Release Classification · 95% confidence The document is a press release titled 'ACTIVITÉS & RÉSULTATS ANNUELS 2021' from Medesis Pharma. It provides a summary of annual financial results, including a table of key figures, management commentary on business activities, clinical trial progress, and future outlook. While it contains financial data, it is a press release (indicated by 'COMMUNIQUE DE PRESSE' headers) rather than a full statutory Annual Report (10-K) or a formal Interim Report (IR). According to the classification rules, this type of summary announcement of annual results is best categorized as an Earnings Release (ER). FY 2021
2022-04-13 French
Medesis Pharma souhaite accélérer le développement de ses produits antinucléaires et fait un point sur sa stratégie
Regulatory Filings Classification · 99% confidence The document is a press release dated April 5, 2022, from Medesis Pharma, titled "Medesis Pharma souhaite accélérer le développement de ses produits antinucléaires et fait un point sur sa stratégie" (Medesis Pharma wishes to accelerate the development of its anti-nuclear products and provides an update on its strategy). It details the status of three drug candidates (NU01, NU02, NP02) intended for protection/decontamination after a nuclear accident, mentions ongoing clinical studies (Phase II in Brazil for NP02), and notes that financing requests have been submitted to the French Defense Innovation Agency. This content is an update on strategy, product development, and financing efforts, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a formal dividend notice. It functions as an investor update providing strategic and operational information. Given the options, it most closely aligns with an Investor Presentation (IP) or a general update that might be released via Regulatory Filings (RNS). However, since it is a detailed strategic update about product pipelines and development plans, 'Investor Presentation' (IP) is a strong fit, although it is presented as a press release/note d'information. Since it is a detailed update on strategy and pipeline progress, often shared with investors, IP is the most appropriate specific category over the general RNS fallback. The length (8325 chars) suggests it is more than a brief announcement (RPA).
2022-04-05 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.